Low molecular weight hydroxyethyl chitosan-prednisolone conjugate for renal targeting therapy: Synthesis, characterization and in vivo studies

Theranostics

Volumn 2, Issue 11, 2012, Pages 1054-1063

  He, Xia Kai ^a   Yuan, Zhi Xiang ^b   Wu, Xiao Juan ^c   Xu, Chao Qun ^b   Li, Wan yu ^d  

^a CHENGDU UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Sichuan Academy of Chinese Medicine Sciences   (China)

^c Integrative Traditional and Western Medicine hospital of Sichuan Province   (China)

^d CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

LMWHC Pre conjugate; MCN model; Osteoporosis; Prednisolone; Renal targeting

Indexed keywords

1 (3 DIMETHYLAMINOPROPYL) 3 ETHYLCARBODIIMIDE; CHITOSAN DERIVATIVE; DAUNORUBICIN; FLUORESCEIN ISOTHIOCYANATE; KROMASIL C18; LOW MOLECULAR WEIGHT HYDROXYETHYLCHITOSAN; N HYDROXYSUCCINIMIDE; PREDNISOLONE; REAGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL ANALYSIS; CHEMICAL COMPOSITION; CONTROLLED STUDY; CROSS COUPLING REACTION; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; IN VIVO STUDY; KIDNEY; KIDNEY NECROSIS; MALE; MINIMAL CHANGE NECROSIS; MOLECULAR WEIGHT; NEPHROTIC SYNDROME; NONHUMAN; OSTEOPOROSIS; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SINGLE DRUG DOSE;

LMWHC-PRE CONJUGATE; MCN MODEL; OSTEOPOROSIS.; PREDNISOLONE; RENAL TARGETING;

ANIMALS; BONE DENSITY; CHITOSAN; DRUG DELIVERY SYSTEMS; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENCE; HYDROGEN-ION CONCENTRATION; KIDNEY; MALE; MICE; MOLECULAR WEIGHT; PREDNISOLONE; RATS; RATS, SPRAGUE-DAWLEY; WHOLE BODY IMAGING;

EID: 84870555393     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.3705     Document Type: Article

References (42)

1. Haverdings RF, Hass M, Navis GJ, Van Loenen-Weemaes AM, Meijer DK, De Zeeuw D, et al. Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in rats. Br J Pharmacol. 2002; 136(8):1107-16.
2. Adachi JD. Glucocorticoid-induced osteoporosis. Osteoporos Int. 2009; 20(3):239-40.
3. Weinstein RS. Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord. 2001; 2(1):65-73.
4. Yuan ZX, Sun X, Gong T, Ding H, Fu Y, Zhang ZR. Randomly 50% N-acetylated low molecular weight chitosan as a novel renal targeting carrier. J Drug Target. 2007; 15(4):269-78.
5. Wilk S, Mizoguchi H, Orlowski M. γ-Glutamyl dopa: A kidney-specific dopamine precursor. J Pharmacol Exp Ther. 1978; 206(1):227-32.
6. Haas M, De Zeeuw D, Van Zanten A, Meijer DK. Quatification of renal low-molecular-weight protein handling in the intact rat. Kidney Int. 1993; 43(4):949-54.
7. Kok RJ, Grijpstra F, Walthuis RB, Moolenaar F, De Zeeuw D, Meijer DK. Specific delivery of captopril to the kidney with the prodrug captopril-lysozyme. J Pharmacol Exp Ther. 1999; 288(1):281-5.
8. Haverdings RF, Haas M, Greupink AR, De Vries PA, Moolenaar F, De Zeeuw D, et al. Potential and limitations of the low molecular-weight protein lysozyme as a carrier for renal drug targeting. Ren Fail. 2001; 23(3-4):397-409.
9. Suzuki K, Susaki H, Okuno S, Sugiyama Y. Renal drug targeting using a vector "alkylgycoside". J Pharmacol Exp Ther. 1999; 288(1):57-64.
10. Suzuki K, Susaki H, Okuno S, Yamada H, Watanabe HK, Sugiyama Y. Specific renal delivery of sugar modified low-molecular-weight peptides. J Pharmacol Exp Ther. 1999; 288(2):888-97.
11. Kamada H, Tsutsumi Y, Sato-Kamada K, Yamamoto Y, Yoshioka Y, Okamoto T, et al. Synthesis of a poly (vinylpyrrolidone-co-dimethyl maleic antydride) co-polymer and its application as renal targeting carrier. Nat Biotechnol. 2003; 21(4):399-404.
12. Kodaira H, Tsutsumi Y, Yoshioka Y, Kamada H, Kaneda Y, Yamamoto Y, et al. The targeting of anionized polyvinylpyrrolidone to the renal system. Biomaterials. 2004; 25(18):4309-15.
13. Yamamoto Y, Tsutsumi Y, Yoshioka Y, Kamada H, Sato-Kamada K, Okamoto T, et al. Poly (vinylprrolidone-co-dimethylmaleic acid) as a novel renal targeting carrier. J Control Release. 2004; 95(2):229-37.
14. Yuan ZX, Zhang ZR, Zhu D, Sun X, Gong T, Liu J, Luan CT. Specific renal uptake of randomly 50% N-acetylated low molecular weight chitosan. Mol Pharm. 2009; 6(1):305-14.
15. Yuan ZX, Li JJ, Zhu D, Sun X, Gong T, Zhang ZR. Enhanced accumulation of low molecular weight chitosan in kidneys: a study on the influence of N-acetylation of chitosan on the renal targeting. J Drug Target. 2011; 19(7):540-51.
16. Mcleod AD, Friend DR, Tozer TN. Glucocorticoid-dextran conjugates as potential prodrugs for colon-specific delivery: Hydrolysis in rat gastrointestinal tract contents. J Pharm Sci. 1994; 83(9):1284-8.
17. Sternberg SS, Philips FS. Biphasic intoxication and nephritic syndrome in rats given daunomycin. Proc Am Assoc Cancer Res, 1967; 8:64-70.
18. Hyung Park J, Kwon S, Lee M, Chung H, Kim JH, Kim YS, et al. Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: In vivo biodistribution and anti-tumor activity. Biomaterials. 2006; 27(1):119-26.
19. Licha K, Olbrich C. Optical imaging in drug discovery and diagnostic applications. Adv Drug Deliv Rev. 2005; 57(8):1087-108.
20. Onishi H, Machida Y. Biodegradation and distribution of water-soluble chitosan in mice. Biomaterials. 1999; 20(2):175-82.
21. Pinaud F, Michalet X, Bentolila LA, Tsay JM, Doose S, Li JJ, et al. Advances in fluorescence imaging with quantum dot bio-probes. Biomaterials. 2006; 27(9):1679-87.
22. Huang M, Ma Z, Khor E, Lim LY. Uptake of FITC-chitosan nanoparticles by A549 cells. Pharma Res. 2002; 19(10):1488-94.
23. Porporatto C, Bianco ID, Correa SG. Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration. J Leukoc Biol. 2005; 78(1):62-9.
24. Kamiyama K, Onishi H, Machida Y. Biodisposition characteristics of N-succinyl-chitosan and glycol-chitosan in normal and tumor bearing mice. Biol Pharm Bull. 1999; 22(2):179-86.
25. Kato Y, Onishi H, Machida Y. Biological characteristics of lactosaminated N-succinyl-chitosan as a liver-specific drug carrier in mice. J Control Release. 2001; 70(3):295-307.
26. Kato Y, Onishi H, Machida Y. N-succinyl-chitosan as a drug carrier: water-insoluble and water-soluble conjugates. Biomaterials. 2004; 25(5):907-15.
27. Xie Y, Tan Y, L Yongbai. Development and advance of minimal change nephropathy model in rats. Chin J Lab Anim Sci. 2001; 11(3):184-87.
28. Nishioka T, Kurayama H, Yasuda T, Udagawa J, Matsumura C, Niimi H. Nasal administration of salmon calcitonin for prevention of glucocorticoid-induced osteoporosis in children with nephrosis. J Pediatr. 1991; 118(5):703-7.
29. Reid IR. Glucocorticoid osteoporosis-mechanisms and management. Eur J Endocrinol. 1997; 137(3):209-17.
30. Lukert BP, Raisz LG. Glucocorticoid-Induced Osteoporosis: Pathogenesis and Management. Ann Intern Med. 1990; 112(5):352-64.
31. Parfitt AM, Villanueva AR, Foldes J, Rao DS. Relations between histologic induces of bone formation: Implications for the pathogenesis of spinal osteoporosis. J Bone Miner Res. 1995; 10(3):466-73.
32. Weinstein RS, Jilka RL, Parffit AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998; 102(2):274-82.
33. Riggs BL, Melton LJ. The prevention and treatment of osteoporosis. N Engl J Med. 1992; 327(9):620-7.
34. Peck WA, Burckhardt P, Christiansen C, Fleisch HA. Consensus development conference: diagnosis; prophylaxis, and treatment of osteoporosis. Am J Med. 1993; 94(6):646-50.
35. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996; 312(7041):1254-9.
36. Melton LJ, Eddy DM, Johnston CC. Screening for osteoporosis. Ann Intern Med. 1990; 112(7):516-28.
37. Law MR, Wald NJ, Meade TW. Strategies for prevention of osteoporosis and hip fracture. BMJ. 1991; 303(6800):453-9.
38. Grisso JA, Kelsey JL, Strom BL, Chiu GY, Maislin G, O'Brien LA, et al. Risk factors for falls as a cause of hip fracture in women. N Engl J Med. 1991; 324(19):1326-31.
39. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. Risk factors for hip fracture in white women. N Engl J Med. 1995; 332(12):767-73.
40. Richards JB, Rivadeneira F, Inouye M, Pastinen TM, Soranzo N, Wilson SG, et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet. 2008; 371(9623):1505-12.
41. Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, et al. Assessment of fracture risk. Osteoporos Int. 2005; 16(6):581-9.
42. Haas M, Moolenaar F, Meijer DK, De Zeeuw D. Specific drug delivery to the kidney. Cardiovasc Drugs Ther. 2002; 16(6):489-96.